Li Keqiong, Chen Yi, Jiang Rong, Chen Dilong, Wang Hong, Xiong Wei, Li Danyang, Liu Zehong, Li Xiaopeng, Li Jing, Yuan Ke
Chongqing Cancer Research Institute, Chongqing 400030, P.R. China.
Laboratory of Stem Cells and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University, Chongqing 400016, P.R. China.
Mol Med Rep. 2017 Aug;16(2):1207-1215. doi: 10.3892/mmr.2017.6685. Epub 2017 Jun 6.
3-O-β-D-xylopyranosyl-6-O-β-D-glucopyranosyl-cycloastragenol, or Astragaloside IV (AST), is one of the major active ingredients isolated from Astragalus membranaceous with distinct pharmacological effects, and possesses anti-inflammatory, immunoregulatory and antifibrotic properties. However, the effects of AST on allergic rhinitis remain to be elucidated. The present study aimed to examine the effects of AST on immunoglobulin (Ig) E‑mediated allergic reactions in vivo, by using a mouse model of allergic rhinitis established via repetitive sensitization and intranasal challenge with ovalbumin (OVA). Intragastric administration of AST (25 mg/kg or 50 mg/kg) or dexamethasone (DEX; 3 mg/kg) significantly alleviated the inflammatory response, nasal symptoms and mucosa remodeling, and decreased the serum levels of OVA‑specific IgE in allergic mice. Furthermore, treatment with AST or DEX significantly suppressed the mRNA and protein expression levels of the transcription factor GATA‑3 and retinoic acid receptor‑related orphan nuclear receptor (ROR)γt in tissue samples isolated from the spleen and nasal mucosa of mice with allergic rhinitis. Conversely, mRNA and protein expression levels of T‑box protein expressed in T cells (T‑bet) and forkhead box protein 3 (Foxp3) were upregulated in the spleen and nasal mucosa of mice with allergic rhinitis following treatment with AST or DEX, and spleen protein levels of signal transducer and activator of transcription 3 followed a similar trend. In addition, treatment with AST was associated with fewer adverse events compared with treatment with DEX. The present results suggested that treatment with AST may attenuate OVA‑induced allergic rhinitis via regulating the expression of the transcription factors GATA‑3, RORγt, T‑bet and Foxp3, which commit T helper cells to the Th1 phenotype. Therefore, AST may represent an alternative therapeutic approach for the treatment of patients with allergic rhinitis.
3 - O - β - D - 吡喃木糖基 - 6 - O - β - D - 吡喃葡萄糖基环黄芪醇，即黄芪甲苷（AST），是从膜荚黄芪中分离出的主要活性成分之一，具有独特的药理作用，具备抗炎、免疫调节和抗纤维化特性。然而，AST对过敏性鼻炎的影响仍有待阐明。本研究旨在通过使用经卵清蛋白（OVA）反复致敏和鼻内激发建立的过敏性鼻炎小鼠模型，来检测AST对体内免疫球蛋白（Ig）E介导的过敏反应的影响。胃内给予AST（25mg/kg或50mg/kg）或地塞米松（DEX；3mg/kg）可显著减轻过敏性小鼠的炎症反应、鼻部症状和黏膜重塑，并降低血清中OVA特异性IgE水平。此外，AST或DEX处理可显著抑制从过敏性鼻炎小鼠的脾脏和鼻黏膜分离的组织样本中转录因子GATA - 3和视黄酸受体相关孤儿核受体（ROR）γt的mRNA和蛋白表达水平。相反，在AST或DEX处理后的过敏性鼻炎小鼠的脾脏和鼻黏膜中，T细胞表达的T - 盒蛋白（T - bet）和叉头框蛋白3（Foxp3）的mRNA和蛋白表达水平上调，并且转录信号转导子和激活子3的脾脏蛋白水平也呈现类似趋势。此外，与DEX治疗相比，AST治疗相关的不良事件更少。本研究结果表明，AST治疗可能通过调节转录因子GATA - 3、RORγt、T - bet和Foxp3的表达来减轻OVA诱导的过敏性鼻炎，这些转录因子可使辅助性T细胞分化为Th1表型。因此，AST可能代表一种治疗过敏性鼻炎患者的替代治疗方法。
